Role of the Spleen Tyrosine Kinase Pathway in Driving Inflammation in IgA Nephropathy
Summary: IgA nephropathy is the most common type of primary glomerulonephritis worldwide. At least 25% of patients may progress to kidney failure requiring dialysis or transplantation. Treatment of IgA nephropathy using generalized immunosuppression is controversial, with concerns regarding the balance of safety and efficacy in a nonspecific approach. This review describes the recent scientific evidence, and a current clinical trial, investigating whether spleen tyrosine kinase (SYK) may be a novel and selective therapeutic target for IgA nephropathy.
Source: Seminars in Nephrology - Category: Urology & Nephrology Authors: Stephen McAdoo, Frederick W.K. Tam Source Type: research
More News: Clinical Trials | Dialysis | Glomerulonephritis | Kidney Transplant | Kidney Transplantation | Transplants | Urology & Nephrology